Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02375958 | PCA062 in pCAD-positive Tumors. | PHASE1 | COMPLETED | 47 | — | — | Apr 15, 2015 | Jul 17, 2018 | Dec 19, 2020 | 7 | United States, France +4 |
| Arm | Type | Description |
|---|---|---|
| Triple Negative Breast Cancer | EXPERIMENTAL | - |
| Head and Neck Cancer | EXPERIMENTAL | - |
| Esophageal Cancer | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PCA062 | DRUG | - |
Inclusion criteria: 1. Male or female ≥ 18 years of age 2. Documented pCAD expressing tumor cells with the exception of HNSCC and ESCC. An archived tumor sample collected within 36 months prior to baseline if available, or a new tumor biopsy sample must be available for molecular pre-screening. 3. ...